[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

June 2019 - April 2015

Decade

Year

Issue

April 2015, Vol 1, No. 1, Pages 3-115

Original Investigation

Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond

Abstract Full Text
free access has audio
JAMA Oncol. 2015;1(1):23-32. doi:10.1001/jamaoncol.2014.168

In a study to derive reliable estimates of cancer risk for CDH1 mutation carriers, Hansford et al conclude that targeted panel sequencing is an efficient way to triage candidate families for broader whole-genome sequencing analysis.

Patient Demands and Requests for Cancer Tests and Treatments

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):33-39. doi:10.1001/jamaoncol.2014.197

In a study to assess patient demands or requests for medical tests or treatments, Gogineni et al found that in fewer than 9% of encounters do patients demand or request tests or treatments, and most of those are clinically appropriate.

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies

Abstract Full Text
open access
JAMA Oncol. 2015;1(1):40-49. doi:10.1001/jamaoncol.2014.216

This genomic profiling study found that almost all carcinomas of unknown primary site harbored at least 1 clinically relevant genomic alteration with potential to influence and personalize therapy.

Association of Actual and Preferred Decision Roles With Patient-Reported Quality of Care: Shared Decision Making in Cancer Care

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):50-58. doi:10.1001/jamaoncol.2014.112

This survey study finds that physician-controlled (vs shared) decision making on cancer treatment is associated with lower ratings of care quality and physician communication.

Population-Based Assessment of Determining Treatments for Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):60-67. doi:10.1001/jamaoncol.2014.192

This study sought to determine population-based predictors for treatment and use of watchful waiting or active surveillance for patients with indolent prostate cancer. The authors found increased use of radiotherapy among these patients, with limited to no correlation with limited to no correlation with tumor biology.. Further research into the contributing factors that drive decision-making recommendations is needed.

Use of Electric Power Morcellation and Prevalence of Underlying Cancer in Women Who Undergo Myomectomy

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):69-77. doi:10.1001/jamaoncol.2014.206

The prevalence of cancer and precancer of the uterus in women who undergo myomectomy with or without electric power morcellation is low, but risk increases with age, so electric power morcellation should be used with caution in older women undergoing myomectomy.

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):80-87. doi:10.1001/jamaoncol.2014.218

Maddocks et al review 4 sequential trials of ibrutinib in patients with chronic lymphocytic leukemia, confirming ibrutinib to be an effective therapy, with outcomes data showing poor prognosis after therapy discontinuation.

Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):88-96. doi:10.1001/jamaoncol.2014.161

Substantial progress has been made in cancer diagnosis and treatment, resulting in a steady improvement in cancer survival. The degree of improvement by age, race, and sex remains unclear. The authors sought to quantify the degree of survival improvement over time by age, race, and sex in the United States. Significant improvements in survival were found for cancers of the colon or rectum, breast, prostate, lung, and liver. Improvements were more pronounced for younger patients.

Research Letter

Clinician Perspectives on Potentially Avoidable Hospitalizations in Patients With Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):109-110. doi:10.1001/jamaoncol.2014.155
Review

Myeloproliferative Neoplasms: A Contemporary Review

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):97-105. doi:10.1001/jamaoncol.2015.89

This review found that stem cell transplant is the current treatment of choice for high-risk myelofibrosis; for all other patients requiring treatment, the authors suggest participation in clinical trials because currently available drugs are palliative and not shown to be disease modifying.

JAMA Oncology Clinical Challenge

Inguinal and Scrotal Lesion

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):107-108. doi:10.1001/jamaoncol.2014.260

A man in his 60s presented for further evaluation of a right inguinal and scrotal rash that had started 4 years prior as a dime-sized, pink, scaly area in the right inguinal crease and was pruritic. What is your diagnosis?

Viewpoint

Losing “Losing the Battle With Cancer”

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):13-14. doi:10.1001/jamaoncol.2014.188

This Viewpoint advocates avoiding use of the phrase “losing the battle with cancer” when a patient dies of advanced disease because the warlike analogies are inappropriate for patients with cancer.

Editorial

Announcing JAMA Oncology

Abstract Full Text
free access has multimedia
JAMA Oncol. 2015;1(1):15-16. doi:10.1001/jamaoncol.2014.239

Hereditary Gastric Cancer: An Update at 15 Years

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):16-18. doi:10.1001/jamaoncol.2014.187

The Myth of the Demanding Patient

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):18-19. doi:10.1001/jamaoncol.2014.185

Carcinoma of Unknown Primary Site: The Poster Child for Personalized Medicine?

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):19-21. doi:10.1001/jamaoncol.2014.277
Invited Commentary

Shared Decision Making in Cancer Care: Does One Size Fit All?

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):58-59. doi:10.1001/jamaoncol.2014.186

Population-Based Assessment of Determining Treatments for Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):67-68. doi:10.1001/jamaoncol.2014.183

The Dilemma of Myomectomy, Morcellation, and the Demand for Reliable Metrics on Surgical Quality

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):78-79. doi:10.1001/jamaoncol.2014.184
JAMA Oncology Patient Page

Immune Checkpoint Inhibitors

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):115. doi:10.1001/jamaoncol.2015.0137
Correction

Error in Byline

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):110. doi:10.1001/jamaoncol.2015.0410

Incorrect and Incomplete Table Headings

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):110. doi:10.1001/jamaoncol.2015.0803
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):8. doi:10.1001/jamaoncol.2014.243
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2015;1(1):3. doi:10.1001/jamaoncol.2015.0650
×